BioSpace News Archive

Investigators sponsored by the National Institutes of Health announced findings from the largest and longest study comparing the effectiveness of common medications to treat type 2 diabetes.

Celcuity Inc., a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, announced the pricing of its underwritten public offering of 2,250,000 shares of its common stock at a price to the public of $25.00 per share.

Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announced that its first-in-class treatment Idefirix® (imlifidase) has received recommendation from the Swedish New Theraphies Council (NT-rådet) for use in the desensitization of highly sensitized adult patients prior to kidney transplant

The event represents the ongoing accomplishments of Humanigen during a transformational year in developing lenzilumab for the treatment of newly hospitalized patients with COVID-19, and its intentions to continue to develop lenzilumab for the treatment of CAR-T, GvHD, and CMML.

The overdose crisis continues to affect communities and families across Canada. Tragically, we have seen substantial increases in overdose deaths and related harms during the COVID-19 pandemic.

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, announced the appointment of Franco Valle as Chief Financial Officer.